{"id":119969,"date":"2025-05-21T14:08:13","date_gmt":"2025-05-21T14:08:13","guid":{"rendered":"https:\/\/www.europesays.com\/uk\/119969\/"},"modified":"2025-05-21T14:08:13","modified_gmt":"2025-05-21T14:08:13","slug":"genetic-data-from-23andme-ends-up-with-this-company-in-256-million-deal","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/uk\/119969\/","title":{"rendered":"Genetic Data From 23andMe Ends Up With This Company In $256 Million Deal"},"content":{"rendered":"\n

Regeneron Pharmaceuticals Inc.<\/strong> (NASDAQ:REGN<\/a>) announced Monday that it has secured the winning bid in the bankruptcy auction for key assets of 23andMe Holding Co.<\/strong> in a $256 million deal<\/a> to boost its genetics-based drug discovery efforts.<\/p>\n

The acquisition includes 23andMe\u2019s Personal Genome Service, Total Health, Research Services divisions, its Biobank, and associated infrastructure. Regeneron plans to keep consumer services running without disruption and expects the transaction to close in the third quarter of 2025.<\/p>\n

Don\u2019t Miss:<\/strong><\/p>\n

Regeneron pledged to uphold 23andMe\u2019s privacy policies to address concerns over data use and comply with all applicable regulations. A court-appointed Customer Privacy Ombudsman will review the intended data use and oversee privacy safeguards throughout the process.<\/p>\n

George D. Yancopoulos, Regeneron\u2019s co-founder and chief scientific officer, emphasized the company\u2019s long-term commitment to leveraging DNA in drug development.<\/p>\n

He noted that Regeneron has already partnered globally to match de-identified genetic information from nearly three million participants with electronic health records, accelerating breakthroughs in treatments for cancer, infectious diseases, and immune disorders.<\/p>\n

Aris Baras, head of the Regeneron Genetics Center, reaffirmed the company\u2019s focus on ethical data use and scientific advancement. He said the acquisition supports Regeneron\u2019s vision of utilizing large-scale genomic research to improve human health.<\/p>\n

Following completion, 23andMe will become a wholly owned subsidiary of Regeneron. The transaction does not include the company\u2019s Lemonaid Health division.<\/p>\n

Regeneron held Cash and marketable securities of $17.625 billion<\/a> as of March 31, 2025.<\/p>\n

Read Next:<\/strong><\/p>\n

Photo by Michael Vi via Shutterstock<\/p>\n

Send To MSN:\u00a0 Send to MSN<\/p>\n

Up Next: Transform your trading with Benzinga Edge’s one-of-a-kind market trade ideas and tools. Click now to access unique insights<\/strong><\/a> that can set you ahead in today’s competitive market.<\/p>\n

Story Continues <\/p>\n","protected":false},"excerpt":{"rendered":"Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) announced Monday that it has secured the winning bid in the bankruptcy auction for…\n","protected":false},"author":2,"featured_media":119970,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3846],"tags":[21326,53600,267,53599,53598,53602,70,53601,16,15],"class_list":{"0":"post-119969","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-genetics","8":"tag-23andme","9":"tag-ai-company","10":"tag-genetics","11":"tag-privacy-policies","12":"tag-regeneron-pharmaceuticals-inc","13":"tag-research-services-divisions","14":"tag-science","15":"tag-total-health","16":"tag-uk","17":"tag-united-kingdom"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@uk\/114546219622388834","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/119969","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/comments?post=119969"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/119969\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media\/119970"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media?parent=119969"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/categories?post=119969"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/tags?post=119969"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}